Wolff M Kirsch, MD, FACS
Chairman & Chief Executive Officer
Wolff Kirsch is a founder and member of the board of directors of Karamedica.
Dr. Kirsch is an established medical innovator with over 40 patents and a seasoned surgeon who practiced neurosurgery. Dr. Kirsch is the co-inventor of an FDA-approved medical device now known as the AnastoClip which is currently sold by LeMaitre Vascular and was previously distributed by US Surgical. Dr. Kirsch helped guide the AnastoClip and its applier through the regulatory process including 510k and PMA. Dr. Kirsch obtained B.A. and M.D. degrees from Washington University in St. Louis followed by neurosurgical residency and a neurochemistry/
Samuel Hudson, PhD
Chief Scientific Officer
Sam Hudson is a founder and a member of the board of directors of Karamedica.
Dr. Hudson is considered one of the world’s leading experts in chitosan with more than 25 years of experience in chitosan research and manipulation. He even attended the first international conference on chitosan and has published over 85 articles and book chapters. Dr. Hudson obtained a B.S. in Chemistry and Textile Chemistry from North Carolina State University followed by Ph.D. training in Fiber and Polymer Science, also at NCSU. Dr. Hudson was a senior chemist with DuPont Co.’s Pioneering Research Lab prior to joining the NCSU College of Textiles in 1987. Dr. Hudson is an established innovator holding 2 patents and the inventor of a number of different physical forms of chitosan and more recently fibroin. He has served on the scientific advisory board of several companies including Nexia Biotechnologies and presently Bolt Threads.
Andrew Crofton, PhD
President & Chief Operating Officer
Andrew Crofton is a founder and a member of the board of directors of Karamedica.
Dr. Crofton is an emerging leader in chitosan research and manipulation as it relates to medicine. He obtained a B.A. in Chemistry and Religion with a Biomedical Studies Concentration from St. Olaf College in 2009. He then completed Loma Linda University School of Medicine’s Integrated Biomedical Graduate Studies PhD program with emphasis in clinical anatomy in 2015 before joining the faculty of Adventist University of Health Sciences. He has 8 years experience in chitosan research, decontamination, and nitrogen plasma sterilization/depyrogenation. Dr. Crofton is the co-inventor on 5 patents or pending patents related to chitosan and Alzheimer’s disease. He is also an experienced leader having served as a mentor for small businesses in the National Science Foundation’s Innovation Corps (I-Corps) and president of several non-profit organizations.
Taub T Swartz, MBA
Chief Financial Officer
Taub Swartz is a co-founder of Karamedica.
After a 20+ year career at Morgan Stanley, Dean Witter ,and Kidder Peabody in capital markets in NYC and London, Taub Swartz is currently the CFO of Codename Enterprises, Inc, parent of Buzzr.com, a web content management company. Taub received his MBA degree from the Stern School of Business at New York University and prior to that earned his BS from the Wharton School of the University of Pennsylvania. He also served for four-years as the president of Boosters of Rhythmic and Artistic Gymnastics, a 501(c)3 organization.. Taub lives in NYC with his wife, two daughters and two dogs!
Eric Gosink, PhD
Senior Vice President – Corporate Strategy
Eric Gosink has extensive experience translating biomedical science into partnership opportunities.
Having spent 19 years in business development, marketing, intellectual property management and licensing, he has served both a commercial and educational role at several research institutions, including St. Jude Children’s Research Hospital, the University of Utah, the UC San Diego, Loma Linda University Health and currently at the UC Riverside where he trains other universities how to commercialize their research, mentors new technology companies and supports a new business
incubator. While in industry, he enabled the launch of new licensing programs in cellular bioproduction and diagnostic instrumentation for Life Technologies Corporation. Dr. Gosink obtained a B.A. in Biochemistry and Cellular Biology from UC San Diego followed by a Ph.D. degree in Physiology from the University of Wisconsin, Madison. He is an author on multiple peer-reviewed scientific publications in physiology and cellular biology.
Kevin Campbell, PhD
Senior Research Scientist
Dr. Campbell graduated from the University of California, Berkeley in 2013 where he majored in Chemical Biology and minored in Bioengineering. He then attended California Polytechnic State University for a master’s in Biomedical Engineering where he did research on new therapies for skin cancer and computational modeling of therapeutic diffusion. From 2015 to 2020, Kevin was a part of the Biomedical Engineering PhD program in the University of California, Davis under the supervision of Professor Eduardo Silva. His research utilized multiple disciplines from his background to model and design vascular based biomaterial delivery strategies for potential tissue regeneration applications. Dr. Campbell has over five years of experience in designing and modeling biomaterial systems for tissue engineering applications including authoring ten scientific publications, presenting at 14 scientific venues and cofounding various scientific platforms to support dissemination of biomaterial research.
Justin Brier-Jones, MS
Research Scientist
Justin Brier-Jones is a staff scientist of Karamedica, Inc. He has a Master’s of Science degree from Loma Linda University with emphasis in clinical anatomy. He has extensive experience working with stem cells and materials science.
OUR SERVICES
OUR TECHNOLOGY
CONTACT US
FOLLOW US
